HIV/AIDS
-
With only 70 Months left to End AIDS, why is the urgency missing?
Globally, 86% people living with HIV knew their status, 89% were on antiretroviral therapy, and 93% of those on antiretroviral therapy were virally suppressed in 2023.
-
Gilead’s twice-yearly injectable PrEP gets FDA approval
Yeztugo’s twice-yearly injection aims to overcome these obstacles by reducing the frequency of dosing and potentially lowering stigma associated with daily medication.
-
Kenya calls for strengthened HIV prevention and maternal health efforts
This call comes amid growing concern over the rising number of new HIV infections among young people, particularly those aged 15 to 24.
-
U.S. FDA halts five Gilead HIV trials due to safety concerns
The safety signal that triggered the FDA’s hold indicates a potential immune system compromise, as reductions in CD4+ T-cells can signal a worsening of HIV infection.
-
Botswana leads Africa in eliminating mother-to-child HIV transmission
The Gold Tier validation confirms Botswana’s success in meeting and surpassing the key indicators required to eliminate mother-to-child transmission of HIV.
-
Global Fund procures African-manufactured ARVs for Mozambique
The ARVs were sourced from Universal Corporation Ltd, a leading pharmaceutical company in Kenya and delivered to Mozambique, where the supplied volume will be sufficient to treat over 72,000 people each year.
-
Zimbabwe reaches pivotal 95-95-95 HIV/AIDS goals
These targets aim to ensure that 95% of people living with HIV know their status, 95% of those diagnosed receive sustained antiretroviral therapy (ART), and 95% of those on treatment achieve viral suppression.
-
TaiMed’s HIV therapy shows strong Phase 2a results
The study highlighted the regimen’s effectiveness in maintaining viral suppression, with an impressive 94% of participants keeping their viral RNA levels below 50 copies/mL throughout the 24-week treatment period.
-
-
